This is the authors' abstract. We don't add key points for this paper.
Insulin icodec is a novel, long-acting, once-weekly basal insulin analog. Its comparative efficacy and safety with basal once-daily insulins in type 2 diabetes mellittus is uncertain.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ribeiro et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: